The United States Food & Drug Administration (USFDA) has inspected Glenmark Pharmaceuticals’ formulation manufacturing facility based out of Goa, India between May 12, 2022 and May 20, 2022. USFDA has issued Form 483 with five observations after an inspection at company’s formulation manufacturing facility in Goa.
The company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
